logo

Denosumab achieved superior bone mineral density gains in head-to-head trial versus weekly alendronate (fosamax)

The incidence and types of adverse events and serious adverse events observed in this study were similar between the denosumab and alendronate treatment groups. The most common adverse events across both treatment arms were arthralgia, back pain, constipation, and dyspepsia.
Read Full Item
http://www.medicalnewstoday.com/articles/109093.php
Date
29th May 2008
Source
Medical News Today